NCT00881153View on ClinicalTrials.gov

To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions.

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

June 30, 2004

Study Completion Date

June 30, 2004

Conditions
Healthy
Interventions
DRUG

Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)

DRUG

Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)

Sponsors

Lead Sponsor

Sandoz
All Listed Sponsors
lead

Sandoz

INDUSTRY

NCT00881153 - To Demonstrate the Relative Bioavailability of Cefzil 250 mg/5 ml Cefprozil Oral Suspension Following a 10 ml Dose Fasting Conditions. | Biotech Hunter | Biotech Hunter